Metabolic Brain Disease

, Volume 28, Issue 2, pp 301–305

Satavaptan treatment for ascites in patients with cirrhosis: a meta-analysis of effect on hepatic encephalopathy development

  • Hugh Watson
  • Peter Jepsen
  • Florence Wong
  • Pere Ginès
  • Juan Córdoba
  • Hendrik Vilstrup
Original Paper


Satavaptan, a vasopressin V2-receptor antagonist, has been shown to improve hyponatraemia in patients with cirrhosis. Hyponatraemia has been associated with an increased risk of hepatic encephalopathy. The objective is to evaluate the efficacy of satavaptan in reducing the risk of new episodes of hepatic encephalopathy. 1,200 patients with cirrhosis and uncomplicated ascites were included in three randomised double-blind studies comparing satavaptan (5–10 mg/day) vs placebo over a one-year treatment period. Effects on incidence of hepatic encephalopathy episodes in individual study and pooled databases were determined with analyses adjusted for hyponatraemia and previous episodes of encephalopathy. Hyponatraemia was improved by satavaptan. Three hundred and ninety-five hepatic encephalopathy episodes were recorded. The risk of an episode and the mean number of episodes were not reduced by satavaptan in any of the three studies in the overall population or in patients who were hyponatraemic on entry. These findings were confirmed in analysis of the pooled data. Satavaptan did not reduce the frequency of hepatic encephalopathy in patients with cirrhosis and ascites.


Satavaptan Vasopressin Hyponatraemia Hepatic encephalopathy 


  1. Angeli P, Wong F, Watson H, Ginès P, CAPPS investigators (2006) Hyponatraemia in cirrhosis: results of a patient population survey. Hepatology 44:1535–1542PubMedCrossRefGoogle Scholar
  2. Cardenas A, Ginès P, Marotta P, Czerwiec F, Oyuang J, Guevara M, Afdhal NH (2012) Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis. J Hepatol 56:571–578PubMedCrossRefGoogle Scholar
  3. Cordoba J, Guevara M, Watson HR, Le Guennec S, Ginès P (2009) Improvement of hyponatremia in cirrhosis increases speed of complex information processing. Hepatology 50(4) (suppl):451AGoogle Scholar
  4. Decaux G, Soupart A, Vassart G (2008) Non-peptide arginine-vasopressin antagonists: the vaptans. Lancet 371:1624–1632PubMedCrossRefGoogle Scholar
  5. Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei A (2002) Hepatic encephalopathy—definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 35:716–721PubMedCrossRefGoogle Scholar
  6. Gerbes AL, Gülberg VA, Ginès P, Decaux G, Gross P, Gandjini H, Djian J, VPA study group (2003) Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized, double-blind multicenter trial. Gastroenterology 124:933–939PubMedCrossRefGoogle Scholar
  7. Ginès P, Wong F, Watson H, Milutinovic S, del Arbol LR, Olteanu D, HypoCAT Study Investigators (2008) Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial. Hepatology 48:204–213PubMedCrossRefGoogle Scholar
  8. Ginès P, Wong F, Watson H, Terg R, Bruha R, Zarski JP, Francis Dudley for the Normocat Study Investigators (2010) Clinical trial: short-term effects of combination of satavaptan, a selective vasopressin V2 receptor antagonist, and diuretics on ascites in patients with cirrhosis without hyponatremia—a randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther 31:834–845PubMedGoogle Scholar
  9. Guevara M, Baccaro ME, Torre A, Gómez-Ansón B, Ríos J, Torres F, Rami L, Monté-Rubio GC, Martín-Llahí M, Arroyo V, Ginès P (2009) Hyponatremia is a risk factor of hepatic encephalopathy in patients with cirrhosis: a prospective study with time-dependent analysis. Am J Gastroenterol 104:1382–1389PubMedCrossRefGoogle Scholar
  10. Guevara M, Baccaro ME, Rios J, Martín-Llahí M, Uriz J, Ruiz del Arbol L, Planas R, Monescillo A, Guarner C, Crespo J, Bañares R, Arroyo V, Ginès P (2010) Risk factors for hepatic encephalopathy in patients with cirrhosis and refractory ascites: relevance of serum sodium concentration. Liver Int. doi:10.1111/j.1478-3231.2010.02293.x
  11. Restuccia T, Gómez-Ansón B, Guevara M, Alessandria C, Torre A, Alayrach ME, Terra C, Martín M, Castellví M, Rami L, Sainz A, Ginès P, Arroyo V (2004) Effects of dilutional hyponatremia on brain organic osmolytes and water content in patients with cirrhosis. Hepatology 39:1613–1622PubMedCrossRefGoogle Scholar
  12. Riggio O, Angeloni S, Salvatori FM, De Santis A, Cerini F, Farcomeni A, Attili AF, Merli M (2008) Incidence, natural history, and risk factors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt with polytetrafluoroethylene-covered stent grafts. Am J Gastroenterol 103:2738–2746PubMedCrossRefGoogle Scholar
  13. Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, Orlandi C, SALT Investigators (2006) Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. New Engl J Med 355:2099–2112PubMedCrossRefGoogle Scholar
  14. Wong F, Ginès P, Watson H, Horsmans Y, Angeli P, Gow P, Minini P, Bernardi M (2010) Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis. J Hepatol 53:283–290Google Scholar
  15. Wong F, Watson H, Gerbes A, Vilstrup H, Badalamenti S, Bernardi M, Ginès P (2012) Satavaptan for the management of ascites in cirrhosis; efficacy and safety across the spectrum of ascites severity. Gut 61:108–116PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Hugh Watson
    • 1
  • Peter Jepsen
    • 2
  • Florence Wong
    • 3
  • Pere Ginès
    • 4
  • Juan Córdoba
    • 5
  • Hendrik Vilstrup
    • 2
  1. 1.Sanofi R&DChilly-MazarinFrance
  2. 2.Department of Medicine V (Hepatology and Gastroenterology)Aarhus University HospitalAarhusDenmark
  3. 3.Toronto General HospitalUniversity of TorontoTorontoCanada
  4. 4.Liver Unit, Hospital Clinic, University of Barcelona, IDIBAPS (Institut d’Investigacions Biomèdiques August Pi-Sunyer), CIBEREHD (Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas)Instituto Reina Sofía de Investigación Nefrológica (IRSIN)BarcelonaSpain
  5. 5.Internal Medicine and Hepatology DepartmentHospital Vall d’Hebron and CIBEREHDBarcelonaSpain

Personalised recommendations